Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 4/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GPR183 | P32249 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | BCR | P11274 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20695401 | 0.89 | KDM1A (0.45) | KDM1AKCNH2MEN1HPGDTSHR | |
| SCHEMBL20695408 | 0.89 | APP (0.43) | FASNKDM1AMGLLKCNH2MEN1 | |
| SCHEMBL20695365 | 0.86 | FASN (0.44) | FASNMGLLGPR183ABL1BCR | |
| SCHEMBL20695169 | 0.86 | MEN1 (0.47) | KDM1AMGLLKCNH2MEN1HPGD | |
| SCHEMBL20695459 | 0.85 | FASN (0.43) | FASNKDM1AMGLLMEN1KMT2A | |
| SCHEMBL20695191 | 0.83 | RXRA (0.46) | MGLLMEN1HPGDTSHRKMT2A | |
| SCHEMBL20695139 | 0.82 | FASN (0.40) | FASNMGLLHPGD | |
| SCHEMBL20695363 | 0.82 | FASN (0.60) | FASNMGLLMEN1HPGDTSHR | |
| SCHEMBL20695328 | 0.82 | ABL1 (0.41) | FASNMGLLGPR183ABL1BCR | |
| SCHEMBL20695131 | 0.82 | ABL1 (0.48) | MGLLGPR183ABL1BCREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10610520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-07 | — | — | US | disclosed |
| US-20190125728-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-02 | — | — | US | disclosed |
| US-20190125728-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-02 | — | — | US | disclosed |
| EP-3438109-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125728-A1 | HETEROCYCLIC COMPOUND | MAG, HTT, ACHE | FASN 3889/4885KDM1A 2299/4885MRGPRX4 518/4885 |
| US-10610520-B2 | Heterocyclic compound | MAG, HTT, ACHE | FASN 3889/4885KDM1A 2299/4885MRGPRX4 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.